411 related articles for article (PubMed ID: 11095432)
1. Lack of suppression of glucagon contributes to postprandial hyperglycemia in subjects with type 2 diabetes mellitus.
Shah P; Vella A; Basu A; Basu R; Schwenk WF; Rizza RA
J Clin Endocrinol Metab; 2000 Nov; 85(11):4053-9. PubMed ID: 11095432
[TBL] [Abstract][Full Text] [Related]
2. Assessment of hepatic sensitivity to glucagon in NIDDM: use as a tool to estimate the contribution of the indirect pathway to nocturnal glycogen synthesis.
Nielsen MF; Wise S; Dinneen SF; Schwenk WF; Basu A; Rizza RA
Diabetes; 1997 Dec; 46(12):2007-16. PubMed ID: 9392488
[TBL] [Abstract][Full Text] [Related]
3. Impact of lack of suppression of glucagon on glucose tolerance in humans.
Shah P; Basu A; Basu R; Rizza R
Am J Physiol; 1999 Aug; 277(2):E283-90. PubMed ID: 10444424
[TBL] [Abstract][Full Text] [Related]
4. Failure of glucagon suppression contributes to postprandial hyperglycaemia in IDDM.
Dinneen S; Alzaid A; Turk D; Rizza R
Diabetologia; 1995 Mar; 38(3):337-43. PubMed ID: 7758881
[TBL] [Abstract][Full Text] [Related]
5. Effect of glucagon-like peptide-1(7-36)-amide on initial splanchnic glucose uptake and insulin action in humans with type 1 diabetes.
Vella A; Shah P; Basu R; Basu A; Camilleri M; Schwenk FW; Holst JJ; Rizza RA
Diabetes; 2001 Mar; 50(3):565-72. PubMed ID: 11246876
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the effects of pioglitazone and metformin on hepatic and extra-hepatic insulin action in people with type 2 diabetes.
Basu R; Shah P; Basu A; Norby B; Dicke B; Chandramouli V; Cohen O; Landau BR; Rizza RA
Diabetes; 2008 Jan; 57(1):24-31. PubMed ID: 17914032
[TBL] [Abstract][Full Text] [Related]
7. Insulin secretion and action and the response of endogenous glucose production to a lack of glucagon suppression in nondiabetic subjects.
Adams JD; Egan AM; Laurenti MC; Schembri Wismayer D; Bailey KR; Cobelli C; Dalla Man C; Vella A
Am J Physiol Endocrinol Metab; 2021 Nov; 321(5):E728-E736. PubMed ID: 34658253
[TBL] [Abstract][Full Text] [Related]
8. Mechanism of action of exenatide to reduce postprandial hyperglycemia in type 2 diabetes.
Cervera A; Wajcberg E; Sriwijitkamol A; Fernandez M; Zuo P; Triplitt C; Musi N; DeFronzo RA; Cersosimo E
Am J Physiol Endocrinol Metab; 2008 May; 294(5):E846-52. PubMed ID: 18334612
[TBL] [Abstract][Full Text] [Related]
9. Effect of overnight restoration of euglycemia on glucose effectiveness in type 2 diabetes mellitus.
Basu R; Basu A; Nielsen M; Shah P; Rizza RA
J Clin Endocrinol Metab; 1999 Jul; 84(7):2314-9. PubMed ID: 10404795
[TBL] [Abstract][Full Text] [Related]
10. Increased action of pulsatile compared to non-pulsatile insulin delivery during a meal-like glucose exposure simulated by computerized infusion in healthy humans.
Juhl CB; Gjedsted J; Nielsen MF; Schmitz O
Metabolism; 2012 Aug; 61(8):1177-81. PubMed ID: 22386942
[TBL] [Abstract][Full Text] [Related]
11. Evidence for increased liver glycogen in patients with noninsulin-dependent diabetes mellitus after a 3-day fast.
Clore JN; Post EP; Bailey DJ; Nestler JE; Blackard WG
J Clin Endocrinol Metab; 1992 Mar; 74(3):660-6. PubMed ID: 1740502
[TBL] [Abstract][Full Text] [Related]
12. Pathogenesis of pre-diabetes: mechanisms of fasting and postprandial hyperglycemia in people with impaired fasting glucose and/or impaired glucose tolerance.
Bock G; Dalla Man C; Campioni M; Chittilapilly E; Basu R; Toffolo G; Cobelli C; Rizza R
Diabetes; 2006 Dec; 55(12):3536-49. PubMed ID: 17130502
[TBL] [Abstract][Full Text] [Related]
13. Effects of glucagon on postprandial carbohydrate metabolism in nondiabetic humans.
Frank JW; Camilleri M; Thomforde GM; Dinneen SF; Rizza RA
Metabolism; 1998 Jan; 47(1):7-12. PubMed ID: 9440470
[TBL] [Abstract][Full Text] [Related]
14. Lack of effect of exendin-4 and glucagon-like peptide-1-(7,36)-amide on insulin action in non-diabetic humans.
Vella A; Shah P; Reed AS; Adkins AS; Basu R; Rizza RA
Diabetologia; 2002 Oct; 45(10):1410-5. PubMed ID: 12378382
[TBL] [Abstract][Full Text] [Related]
15. Impaired first-phase insulin response predicts postprandial blood glucose increment in patients with recently diagnosed type 2 diabetes.
Gredal C; Rosenfalck AM; Dejgaard A; Hilsted J
Scand J Clin Lab Invest; 2007; 67(3):327-36. PubMed ID: 17454847
[TBL] [Abstract][Full Text] [Related]
16. Type I diabetes mellitus does not alter initial splanchnic glucose extraction or hepatic UDP-glucose flux during enteral glucose administration.
Vella A; Shah P; Basu R; Basu A; Camilleri M; Schwenk WF; Rizza RA
Diabetologia; 2001 Jun; 44(6):729-37. PubMed ID: 11440366
[TBL] [Abstract][Full Text] [Related]
17. Glucosamine-induced inhibition of liver glucokinase impairs the ability of hyperglycemia to suppress endogenous glucose production.
Barzilai N; Hawkins M; Angelov I; Hu M; Rossetti L
Diabetes; 1996 Oct; 45(10):1329-35. PubMed ID: 8826967
[TBL] [Abstract][Full Text] [Related]
18. Regulation of endogenous glucose production by glucose per se is impaired in type 2 diabetes mellitus.
Mevorach M; Giacca A; Aharon Y; Hawkins M; Shamoon H; Rossetti L
J Clin Invest; 1998 Aug; 102(4):744-53. PubMed ID: 9710443
[TBL] [Abstract][Full Text] [Related]
19. Glucose-induced suppression of endogenous glucose production: dynamic response to differing glucose profiles.
Vella A; Reed AS; Charkoudian N; Shah P; Basu R; Basu A; Joyner MJ; Rizza RA
Am J Physiol Endocrinol Metab; 2003 Jul; 285(1):E25-30. PubMed ID: 12637258
[TBL] [Abstract][Full Text] [Related]
20. Effects of hepatic glycogen content on hepatic insulin action in humans: alteration in the relative contributions of glycogenolysis and gluconeogenesis to endogenous glucose production.
Wise S; Nielsen M; Rizza R
J Clin Endocrinol Metab; 1997 Jun; 82(6):1828-33. PubMed ID: 9177391
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
